NCT06349642 - Predicting Response to Immune Checkpoint Inhibitors Across Solid Tumors Using a Live Tumor Diagnostic Platform | Biotech Hunter

Enrollment

324

Participants

Timeline

Start Date

April 24, 2024

Primary Completion Date

May 31, 2027

Study Completion Date

May 31, 2027

Conditions

Early Stage Triple-Negative Breast CarcinomaMetastatic Bladder Urothelial CarcinomaMetastatic Cervical CarcinomaMetastatic Clear Cell Renal Cell CarcinomaMetastatic Colorectal CarcinomaMetastatic Endometrial CarcinomaMetastatic Esophageal CarcinomaMetastatic Liver CarcinomaMetastatic Lung Non-Small Cell CarcinomaMetastatic Malignant Skin NeoplasmMetastatic Malignant Solid NeoplasmResectable Lung Non-Small Cell CarcinomaEarly Stage Lung Non-Small Cell CarcinomaResectable Malignant Solid NeoplasmResectable Triple-Negative Breast CarcinomaStage III Renal Cell Cancer AJCC v8Stage IV Cervical Cancer AJCC v8Stage IV Renal Cell Cancer AJCC v8Stage IV Uterine Corpus Cancer AJCC v8

Interventions

PROCEDURE

Biospecimen Collection

Undergo optional research blood sample.

PROCEDURE

Tissue Collection

Tissue specimen collection will be completed with your scheduled standard of care biopsy if possible. If standard of care biopsy is already completed or the research biopsy wasn\'t collected at the time as your standard of care biopsy, then the research biopsy will be scheduled for a different day for research purposes only.

Trial Locations (1)

32224

RECRUITING

Mayo Clinic in Florida, Jacksonville